Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
GRIK1 2897 CHEMBL301536 CHEMBL301536 agonist GuideToPharmacologyInteractions
GRIK1 2897 MESALAMINE CHEMBL704 agonist GuideToPharmacologyInteractions
GRIK1 2897 CHEMBL274226 CHEMBL274226 antagonist GuideToPharmacologyInteractions
GRIK1 2897 DASOLAMPANEL CHEMBL2103869 antagonist ChemblInteractions
GRIK1 2897 TOPIRAMATE CHEMBL220492 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 12724156, 11752352, 15111016, 12904467, 19417176
GRIK1 2897 CHEMBL113180 CHEMBL113180 agonist GuideToPharmacologyInteractions
GRIK1 2897 CHEMBL28472 CHEMBL28472 agonist GuideToPharmacologyInteractions
GRIK1 2897 2S,4R-4-METHYLGLUTAMATE CHEMBL288166 agonist GuideToPharmacologyInteractions
GRIK1 2897 CHEMBL373429 CHEMBL373429 antagonist GuideToPharmacologyInteractions
GRIK1 2897 CHEMBL156717 CHEMBL156717 antagonist GuideToPharmacologyInteractions
GRIK1 2897 Selurampanel CHEMBL3545042 antagonist ChemblInteractions
GRIK1 2897 CHEMBL121915 CHEMBL121915 agonist GuideToPharmacologyInteractions
GRIK1 2897 CHEMBL373428 CHEMBL373428 antagonist GuideToPharmacologyInteractions
GRIK1 2897 TEZAMPANEL CHEMBL14935 antagonist TdgClinicalTrial, ChemblInteractions, TTD
GRIK1 2897 L-GLUTAMATE CHEMBL575060 DrugBank 9254673, 17139284, 17016423, 10513575, 13129570
GRIK1 2897 CHEMBL426 CHEMBL426 agonist GuideToPharmacologyInteractions
GRIK1 2897 DOMOIC ACID CHEMBL1232313 agonist GuideToPharmacologyInteractions
GRIK1 2897 KAINIC ACID CHEMBL275040 agonist GuideToPharmacologyInteractions
GRIK1 2897 METHYPRYLON CHEMBL1200790 allosteric modulator GuideToPharmacologyInteractions
GRIK1 2897 CHEMBL372797 CHEMBL372797 antagonist GuideToPharmacologyInteractions
GRIK1 2897 CHEMBL387049 CHEMBL387049 TdgClinicalTrial

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
GRIK1 rs2832407 AA + AC topiramate efficacy yes 75.5% of participants met the criteria for an alcohol use disorder. At target dose (week 5 of treatment), carriers of the A allele reported a higher percentage of heavy drinking days (%HDD), as compared to those with the CC genotype (controlling for baseline %HDD). Genotypes AA + AC is associated with decreased response to topiramate in people with Alcohol-Related Disorders as compared to genotype CC. 19331489 1184749261
GRIK1 rs2832407 AA + AC topiramate metabolism/PK yes 75.5% of participants met the criteria for an alcohol use disorder. At target dose (week 5 of treatment), carriers of the A allele had higher serum topiramate levels as compared to those with the CC genotype. No association was seen with dose. Genotypes AA + AC is associated with increased concentrations of topiramate in people with Alcohol-Related Disorders as compared to genotype CC. 19331489 1184749254